Technical Data
D8060-03
Dinitrophenol (DNP)
|
Technical Data |
|
D8060-03 |
Dinitrophenol (DNP) |
|
|
Description: Asthma is a chronic lung disease characterized by airway hyper-responsiveness (AHR) to allergens, airway edema, and increased mucus secretion. Increased levels of circulating IgE and IgG1 antibody and a propensity to allergic responses, atopy, are associated with the development of asthma. Animal models of AHR, where control of the timing of exposure to the initiating antigen, the use of a defined allergen trigger, and genetic manipulation are likely to enhance the understanding of AHR. Dinitrophenol (DNP) has long been employed as a model immunogen as a single antigen to reduce the complexity of modeling AHR. One of the primary aspects of the immune response is the interaction of antigens with lymphocytes to induce the formation of antibodies, that in turn makes the antigen harmless. Much of our current understanding of the antibody response to antigens has been derived by using the antibody-hapten model. One known model uses the dinitrophenyl (DNP) group. Immunization of many mammalian species with DNP-protein conjugates results in production of antibodies specific for DNP and the amino acid side chains to which it is attached. Applications: Suitable for use in ELISA. Other applications not tested. Recommended Dilution: ELISA: 0.5-1 ug/ml Optimal dilutions to be determined by the researcher. Storage and Stability: May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. |
|
|||||||||||
|
||||||||||||
|
||||||||||||
|
||||||||||||